Andreas Hüttmann
0000-0003-2230-3873
9 papers found
Refreshing results…
Baseline PET radiomics outperform the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma
Baseline radiomics features and MYC rearrangement status predict progression in aggressive B-cell lymphoma
A tumor volume and performance status model to predict outcome before treatment in diffuse large B-cell lymphoma
Proposed New Dynamic Prognostic Index for Diffuse Large B-Cell Lymphoma: International Metabolic Prognostic Index
Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA)
Reinduction therapy with everolimus in combination with dexamethasone, high‐dose cytarabin and cisplatinum in patients with relapsed or refractory classical Hodgkin lymphoma: an experimental phase I/II multicentre trial of the German Hodgkin Study Group (GHSG HD‐R3i)
Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA
Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients
Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma
Missing publications? Search for publications with a matching author name.